Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: alzheimerascendingand pharmacodynamicstolerabilitypharmacodynamics of
  Phrases that lowered it: healthygreater thandaysprescriptionstudy
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 9.8% (raises risk) · Sponsor's track record
• Maximum age: 99 (lowers risk) · Who can join
• Blinding: triple (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 129 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients NCT01485302 · started 2012 · scored riskier than 60% of active trials completed
• Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 NCT03298672 · started 2017 · scored riskier than 14% of active trials completed
• Study Evaluating the Safety and Tolerability of NSA-789 NCT00633048 · started 2008 · scored riskier than 6% of active trials completed
• Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease NCT00895895 · started 2009 · scored riskier than 64% of active trials terminated
• A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease NCT03375697 · started 2017 · scored riskier than 39% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.